Skip to main content

Melphalan News

Melphalan/Hepatic Delivery System Beneficial for Metastatic Uveal Melanoma

THURSDAY, April 24, 2025 – For patients with unresectable metastatic uveal melanoma (mUM), the drug/device combination melphalan/hepatic delivery system (HDS) is efficacious and has a favorable...

FDA Approves Hepzato Kit (melphalan) Hepatic Delivery System for the Treatment of Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

NEW YORK, Aug. 14, 2023 /PRNewswire/ – Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced ...

FDA Approves Pepaxto (melphalan flufenamide) for Patients with Relapsed or Refractory Multiple Myeloma

STOCKHOLM, Feb. 26, 2021 /PRNewswire/ – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological...

FDA Grants Spectrum Pharmaceuticals Approval of Evomela (melphalan) for Injection

HENDERSON, Nev., March 15, 2016 --(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Multiple Myeloma, Ovarian Cancer

Melphalan patient information at Drugs.com